McKesson Posts Fiscal Q2 Results, Lifts Full-Year Adjusted EPS Guidance
MCK sits 48% above its 52-week low of $723.68.
Summary
McKesson released fiscal 2027 second-quarter results and raised its full-year adjusted EPS guidance. The press release itself carries no figures — the numbers sit in the earnings release and slide deck posted to the investor relations site, with the conference call at 4:30 PM ET today. The raise is the part that matters: it follows the September guidance lift to $44.20–$45.00 in adjusted EPS, so management is adding to an already-raised outlook rather than resetting it. Shares are trading near a 52-week high of $1,073.95, so expectations are elevated going into the call. Context to keep in mind: the pending ~$2.25B Precision Medicine Group acquisition, the CVS distribution partnership extension, and the joint $32.05-per-share Option Care Health deal with CD&R all sit outside this quarter's core distribution results. The 4:30 PM ET call is where the size of the raise and any segment detail will land.
At the time of this announcement, MCK was trading at $1,069.44 on NYSE in the Trade & Services sector, with a market capitalization of approximately $124.7B. The 52-week trading range was $723.68 to $1,073.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.